NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted Cepheid clearance to market the Xpert Carba-R test, the firm announced today.

According to the company, it is the first FDA-cleared test to detect and differentiate carbapenemase genes in pure bacterial isolates that were previously determined to be non-responsive to carbapenem antibiotics, considered the last line of defense to treat infections. The test identifies 5 families of carbapenem resistance genes in carbapenem-producing organisms (CPOs), including KPC, NDM, VIM, OXA-48, and IMP.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.